UiPath ARR Hits $1.94B, Above Guided Range, but Monetization Concerns Persist

What happened

UiPath's annual recurring revenue (ARR) reached $1.94 billion in the second quarter of fiscal 2027, slightly above the company's guided range of $1.929–1.934 billion. This growth reflects sustained enterprise demand for AI-driven automation, as the company continues to convert its agentic automation positioning into larger deals. However, the article also notes that competition and monetization challenges remain, echoing the master report's bear concerns about bundling pressure and retention risks. The master report had set a key checkpoint: Q2 ARR above the guided range would support the thesis, while a miss would weaken it. Therefore, the ARR beat is a modest positive, but the market will now look for confirmation of net revenue retention and net-new ARR sustainability to gauge the durability of growth.

Implication

The ARR beat above guidance suggests that UiPath's enterprise demand is holding up better than feared, supporting the base case valuation of $12.50 per share. However, without evidence of stable or improving net revenue retention (NRR) and net-new ARR, the stock may struggle to re-rate toward the bull case of $16. The master report's thesis remains contingent on NRR staying above 108% and net-new ARR sustaining around $40–60 million per quarter; investors should monitor these metrics in the upcoming quarterly report. Competition from suite vendors like Microsoft and monetization of AI features remain key risks, and any deterioration in these areas could push the stock toward the bear case of $8. Given the current price around $10.90 and the demonstrated ARR growth, the risk-reward remains balanced, with a potential upside to $12.50 if the company continues to execute.

Thesis delta

The Q2 FY27 ARR print of $1.94 billion (above the guided range) satisfies a key positive checkpoint from the master report, signaling that enterprise automation demand remains robust. This shifts the thesis slightly more positive, but the persistence of monetization challenges and uncertain NRR keeps conviction at 'Medium' rather than upgrading to a stronger buy. The thesis remains a 'POTENTIAL BUY' with a base case value of $12.50, but investors should wait for confirmation of retention metrics before increasing exposure.